| Bilal A Mian, MD | |
|
5605 W Eugie Ave Ste 110, Glendale, AZ 85304-1273 | |
| (623) 847-2000 | |
| Not Available |
| Full Name | Bilal A Mian |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 31 Years |
| Location | 5605 W Eugie Ave Ste 110, Glendale, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679563647 | NPI | - | NPPES |
| 819807 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 25609 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Howard John Simon Md Pc | 1658602263 | 26 |
| Banner Imaging Services Llc | 1850724386 | 90 |
| Smi Imaging Llc | 3476696220 | 239 |
| Simonmed Imaging Florida Llc | 6608036108 | 152 |
| Howard Simon Md Pc | 7214369966 | 24 |
| Associated Valley Radiologists Ltd | 8325388499 | 41 |
News Archive
Sucampo Pharmaceuticals, Inc., has announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA).
Writing in the May 14, 2021 issue of The American Journal of Psychiatry, a multi-institution team of scientists led by researchers at University of California San Diego School of Medicine report that medications commonly prescribed to reduce the severity of physical and mental health symptoms associated with schizophrenia may have a cumulative effect of worsening cognitive function in patients.
Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect.
Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.
Michigan State University's new Goldwater Scholars for 2004 have a lot of work ahead of them – studying compounds shown to prevent cancer drug resistance and studying tomato genes and proteins.
› Verified 5 days ago
| Entity Name | Southwest Diagnostic Imaging Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902896236 PECOS PAC ID: 7416946199 Enrollment ID: O20040507001294 |
News Archive
Sucampo Pharmaceuticals, Inc., has announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA).
Writing in the May 14, 2021 issue of The American Journal of Psychiatry, a multi-institution team of scientists led by researchers at University of California San Diego School of Medicine report that medications commonly prescribed to reduce the severity of physical and mental health symptoms associated with schizophrenia may have a cumulative effect of worsening cognitive function in patients.
Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect.
Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.
Michigan State University's new Goldwater Scholars for 2004 have a lot of work ahead of them – studying compounds shown to prevent cancer drug resistance and studying tomato genes and proteins.
› Verified 5 days ago
| Entity Name | Page Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1578515789 PECOS PAC ID: 5496665861 Enrollment ID: O20110328000098 |
News Archive
Sucampo Pharmaceuticals, Inc., has announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA).
Writing in the May 14, 2021 issue of The American Journal of Psychiatry, a multi-institution team of scientists led by researchers at University of California San Diego School of Medicine report that medications commonly prescribed to reduce the severity of physical and mental health symptoms associated with schizophrenia may have a cumulative effect of worsening cognitive function in patients.
Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect.
Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.
Michigan State University's new Goldwater Scholars for 2004 have a lot of work ahead of them – studying compounds shown to prevent cancer drug resistance and studying tomato genes and proteins.
› Verified 5 days ago
| Entity Name | Banner Hospital Based Physicians Arizona Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275889891 PECOS PAC ID: 3274782487 Enrollment ID: O20121003000752 |
News Archive
Sucampo Pharmaceuticals, Inc., has announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA).
Writing in the May 14, 2021 issue of The American Journal of Psychiatry, a multi-institution team of scientists led by researchers at University of California San Diego School of Medicine report that medications commonly prescribed to reduce the severity of physical and mental health symptoms associated with schizophrenia may have a cumulative effect of worsening cognitive function in patients.
Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect.
Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.
Michigan State University's new Goldwater Scholars for 2004 have a lot of work ahead of them – studying compounds shown to prevent cancer drug resistance and studying tomato genes and proteins.
› Verified 5 days ago
| Entity Name | Simonmed Imaging Florida Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477830818 PECOS PAC ID: 6608036108 Enrollment ID: O20160712002225 |
News Archive
Sucampo Pharmaceuticals, Inc., has announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA).
Writing in the May 14, 2021 issue of The American Journal of Psychiatry, a multi-institution team of scientists led by researchers at University of California San Diego School of Medicine report that medications commonly prescribed to reduce the severity of physical and mental health symptoms associated with schizophrenia may have a cumulative effect of worsening cognitive function in patients.
Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect.
Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.
Michigan State University's new Goldwater Scholars for 2004 have a lot of work ahead of them – studying compounds shown to prevent cancer drug resistance and studying tomato genes and proteins.
› Verified 5 days ago
| Entity Name | Smi Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972004489 PECOS PAC ID: 3476696220 Enrollment ID: O20180829003142 |
News Archive
Sucampo Pharmaceuticals, Inc., has announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA).
Writing in the May 14, 2021 issue of The American Journal of Psychiatry, a multi-institution team of scientists led by researchers at University of California San Diego School of Medicine report that medications commonly prescribed to reduce the severity of physical and mental health symptoms associated with schizophrenia may have a cumulative effect of worsening cognitive function in patients.
Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect.
Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.
Michigan State University's new Goldwater Scholars for 2004 have a lot of work ahead of them – studying compounds shown to prevent cancer drug resistance and studying tomato genes and proteins.
› Verified 5 days ago
| Entity Name | Associated Valley Radiologists Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932683257 PECOS PAC ID: 8325388499 Enrollment ID: O20190327003225 |
News Archive
Sucampo Pharmaceuticals, Inc., has announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA).
Writing in the May 14, 2021 issue of The American Journal of Psychiatry, a multi-institution team of scientists led by researchers at University of California San Diego School of Medicine report that medications commonly prescribed to reduce the severity of physical and mental health symptoms associated with schizophrenia may have a cumulative effect of worsening cognitive function in patients.
Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect.
Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.
Michigan State University's new Goldwater Scholars for 2004 have a lot of work ahead of them – studying compounds shown to prevent cancer drug resistance and studying tomato genes and proteins.
› Verified 5 days ago
| Entity Name | Banner Imaging Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770139958 PECOS PAC ID: 1850724386 Enrollment ID: O20191213001312 |
News Archive
Sucampo Pharmaceuticals, Inc., has announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA).
Writing in the May 14, 2021 issue of The American Journal of Psychiatry, a multi-institution team of scientists led by researchers at University of California San Diego School of Medicine report that medications commonly prescribed to reduce the severity of physical and mental health symptoms associated with schizophrenia may have a cumulative effect of worsening cognitive function in patients.
Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect.
Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.
Michigan State University's new Goldwater Scholars for 2004 have a lot of work ahead of them – studying compounds shown to prevent cancer drug resistance and studying tomato genes and proteins.
› Verified 5 days ago
| Entity Name | Howard Simon Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659930998 PECOS PAC ID: 7214369966 Enrollment ID: O20200123001656 |
News Archive
Sucampo Pharmaceuticals, Inc., has announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA).
Writing in the May 14, 2021 issue of The American Journal of Psychiatry, a multi-institution team of scientists led by researchers at University of California San Diego School of Medicine report that medications commonly prescribed to reduce the severity of physical and mental health symptoms associated with schizophrenia may have a cumulative effect of worsening cognitive function in patients.
Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect.
Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.
Michigan State University's new Goldwater Scholars for 2004 have a lot of work ahead of them – studying compounds shown to prevent cancer drug resistance and studying tomato genes and proteins.
› Verified 5 days ago
| Entity Name | Howard John Simon Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932768934 PECOS PAC ID: 1658602263 Enrollment ID: O20200124000220 |
News Archive
Sucampo Pharmaceuticals, Inc., has announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA).
Writing in the May 14, 2021 issue of The American Journal of Psychiatry, a multi-institution team of scientists led by researchers at University of California San Diego School of Medicine report that medications commonly prescribed to reduce the severity of physical and mental health symptoms associated with schizophrenia may have a cumulative effect of worsening cognitive function in patients.
Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect.
Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.
Michigan State University's new Goldwater Scholars for 2004 have a lot of work ahead of them – studying compounds shown to prevent cancer drug resistance and studying tomato genes and proteins.
› Verified 5 days ago
| Entity Name | Health Diagnostics Of California A Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104321959 PECOS PAC ID: 4284621525 Enrollment ID: O20200313001484 |
News Archive
Sucampo Pharmaceuticals, Inc., has announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA).
Writing in the May 14, 2021 issue of The American Journal of Psychiatry, a multi-institution team of scientists led by researchers at University of California San Diego School of Medicine report that medications commonly prescribed to reduce the severity of physical and mental health symptoms associated with schizophrenia may have a cumulative effect of worsening cognitive function in patients.
Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect.
Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.
Michigan State University's new Goldwater Scholars for 2004 have a lot of work ahead of them – studying compounds shown to prevent cancer drug resistance and studying tomato genes and proteins.
› Verified 5 days ago
| Entity Name | Sonoran Radiology Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033745708 PECOS PAC ID: 3375964505 Enrollment ID: O20200526002412 |
News Archive
Sucampo Pharmaceuticals, Inc., has announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA).
Writing in the May 14, 2021 issue of The American Journal of Psychiatry, a multi-institution team of scientists led by researchers at University of California San Diego School of Medicine report that medications commonly prescribed to reduce the severity of physical and mental health symptoms associated with schizophrenia may have a cumulative effect of worsening cognitive function in patients.
Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect.
Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.
Michigan State University's new Goldwater Scholars for 2004 have a lot of work ahead of them – studying compounds shown to prevent cancer drug resistance and studying tomato genes and proteins.
› Verified 5 days ago
| Entity Name | Toca At Banner Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386270932 PECOS PAC ID: 3072934777 Enrollment ID: O20200604003160 |
News Archive
Sucampo Pharmaceuticals, Inc., has announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA).
Writing in the May 14, 2021 issue of The American Journal of Psychiatry, a multi-institution team of scientists led by researchers at University of California San Diego School of Medicine report that medications commonly prescribed to reduce the severity of physical and mental health symptoms associated with schizophrenia may have a cumulative effect of worsening cognitive function in patients.
Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect.
Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.
Michigan State University's new Goldwater Scholars for 2004 have a lot of work ahead of them – studying compounds shown to prevent cancer drug resistance and studying tomato genes and proteins.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bilal A Mian, MD 2323 W Rose Garden Ln, Phoenix, AZ 85027-2530 Ph: (623) 931-7999 | Bilal A Mian, MD 5605 W Eugie Ave Ste 110, Glendale, AZ 85304-1273 Ph: (623) 847-2000 |
News Archive
Sucampo Pharmaceuticals, Inc., has announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA).
Writing in the May 14, 2021 issue of The American Journal of Psychiatry, a multi-institution team of scientists led by researchers at University of California San Diego School of Medicine report that medications commonly prescribed to reduce the severity of physical and mental health symptoms associated with schizophrenia may have a cumulative effect of worsening cognitive function in patients.
Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect.
Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.
Michigan State University's new Goldwater Scholars for 2004 have a lot of work ahead of them – studying compounds shown to prevent cancer drug resistance and studying tomato genes and proteins.
› Verified 5 days ago
Dr. Perry S Hiscok, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 7111 W Bell Rd, Suite 104, Glendale, AZ 85308 Phone: 623-533-4465 | |
Dr. Murali G Murty, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5810 W Beverly Ln, Glendale, AZ 85306 Phone: 623-312-3000 Fax: 623-312-3060 | |
Dr. Abhinav P Patel, MD Radiology Medicare: Medicare Enrolled Practice Location: 5555 W Thunderbird Rd, Glendale, AZ 85306 Phone: 602-865-5555 | |
Phillip M Moeser, MD Radiology Medicare: Medicare Enrolled Practice Location: 5322 W Northern Ave, Southwest Diagnostic Imaging Ltd, Glendale, AZ 85301 Phone: 480-425-5063 Fax: 623-915-6924 | |
Denise J Smith, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5605 W Eugie Ave Ste 110, Glendale, AZ 85304 Phone: 623-847-2000 | |
Patrick R Miller, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5810 W Beverly Ln, Glendale, AZ 85306 Phone: 623-312-3000 Fax: 623-312-3060 | |
Dr. Raul Galvez-trevino, M.D., M.P.H. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5605 W Eugie Ave Ste 110, Glendale, AZ 85304 Phone: 623-847-2000 |